analogous oseltamivir phosphate capsule — Competitive Intelligence Brief

analogous oseltamivir phosphate capsule (analogous oseltamivir phosphate capsule) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuraminidase inhibitor. Area: Infectious Disease.

phase 3 Neuraminidase inhibitor Neuraminidase Infectious Disease Small molecule

Target snapshot

analogous oseltamivir phosphate capsule (analogous oseltamivir phosphate capsule) — The First Affiliated Hospital of Guangzhou Medical University. Oseltamivir phosphate is a prodrug that is metabolized to oseltamivir carboxylate, which acts as a potent inhibitor of influenza virus neuraminidase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
analogous oseltamivir phosphate capsule TARGET	analogous oseltamivir phosphate capsule	The First Affiliated Hospital of Guangzhou Medical University	phase 3	Neuraminidase inhibitor	Neuraminidase
Oseltamivir phosphate granules	Oseltamivir phosphate granules	China Academy of Chinese Medical Sciences	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Oseltamivir Phosphate For Oral Suspension	Oseltamivir Phosphate For Oral Suspension	The Affiliated Hospital of Qingdao University	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)
Oseltamivir(oral)	Oseltamivir(oral)	Guangdong Raynovent Biotech Co., Ltd	marketed	Neuraminidase inhibitor	Influenza neuraminidase
active oseltamivir	active oseltamivir	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuraminidase inhibitor class)

1. University of Oxford · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Guangdong Raynovent Biotech Co., Ltd · 2 drugs in this class
4. UMC Utrecht · 2 drugs in this class
5. Genuine Research Center, Egypt · 1 drug in this class
6. The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class
7. China Academy of Chinese Medical Sciences · 1 drug in this class
8. Hoffmann-La Roche · 1 drug in this class
9. National Institute for Public Health and the Environment (RIVM) · 1 drug in this class
10. The Affiliated Hospital of Qingdao University · 1 drug in this class